Biktarvy + doxycycline

Biktarvy + doxycycline refers to a combination prophylaxis regimen being evaluated in the Phase 4 Combo-PEP clinical trial (NCT04860505) conducted by Emory University. This regimen consists of Biktarvy—a fixed-dose combination tablet containing bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg)—co-administered with doxycycline (200 mg). Biktarvy is an FDA-approved antiretroviral therapy that targets HIV-1 integrase and reverse transcriptase. Doxycycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. The study investigates the tissue pharmacology and efficacy of this combination for multipurpose post-exposure prophylaxis (PEP) to prevent both HIV-1 and bacterial sexually transmitted infections (STIs), such as syphilis, chlamydia, and gonorrhea, in men who have sex with men (MSM) and women.

Brand names

Biktarvy

Other names

Biktarvy-Emory University-sexually transmitted diseasesbictegravir + emtricitabine + tenofovir alafenamide + doxycycline